News | Radiation Therapy | February 10, 2016

Missing two radiotherapy appointments may impair tumor control, particularly for head and neck cancers

radiation therapy, missing appointments, cancer recurrence, Montefiore Medical Center

February 10, 2016 — Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators in a new study have found.

The study was conducted by investigators at Montefiore Einsten Center for Cancer Care and Albert Einstein College of Medicine’s NCI-designated Albert Einstein Cancer Center. It was published in the International Journal of Radiation Oncology Biology Physics.

The results suggest that this noncompliance to scheduled treatments may represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.

The study evaluated 1,227 patients scheduled for courses of external beam radiation therapy for cancers of the head and neck, breast, lung, cervix uterus or rectum from 2007 to 2012. Two hundred twenty-six of these patients (22 percent) were noncompliant (i.e., they missed two or more scheduled radiation therapy appointments). All patients eventually completed the radiation therapy course planned for them.

The radiation therapy course for noncompliant patients was prolonged for an average of one week compared with compliant patients. Nevertheless, 16 percent of noncompliant patients later experienced a recurrence of their cancers versus only a 7 percent recurrence rate for compliant patients.

“This study shows that the health of our patients can improve only when a course of treatment is completed in the prescribed period of time,” said Madhur Garg, M.D., clinical director, Department of Radiation Oncology, MECCC and professor of clinical radiation oncology at Einstein. “These findings should serve as a wakeup call to physicians, patients and their caregivers about the critical need to adhere to a recommended treatment schedule.”

Prolonging radiation therapy for head and neck cancer or cervical cancer impacted tumor control and overall survival at the greatest rate, at 1 percent per day, however this negative impact was seen in all cancers studied. This is attributed to tumor repopulation, which can accelerate after treatment initiation.

“We previously conducted a study that demonstrated a statistically significant relationship between lower socioeconomic status and non-compliance,” said Nitin Ohri, M.D., attending physician, MECCC and assistant professor of radiation oncology at Einstein. “A Multivariable Cox proportional hazard model was informed by this prior study and helped us adjust for demographic variables like age, race, ethnicity and socioeconomic status.”

As an outcome result of this study, management of mood disorders, patient navigator programs and increasing assistance with transportation are being evaluated at Montefiore as interventions that might improve patient care outcomes and close disparities among vulnerable populations.

For more information: www.redjournal.org


Related Content

News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Focused Ultrasound Therapy

Aug. 26, 2025 — In a quest for ever-more-effective treatments for pancreatic cancer, HonorHealth Research Institute is ...

Time August 29, 2025
arrow
Subscribe Now